A clinical study of the pharmacokinetics, efficacy and safety of an investigational intravenous drug in subjects with primary immune deficiency diseases

The goal of this study is to assess the effects of an investigational IVIG drug in subjects with primary immune deficiency diseases.  The study will include 13 or 17 infusions (on a 21 or 28 day schedule) and last 16 months.

You may be eligible to participate in this study if you:

• Are between 3 and 75 years of age
• Have a diagnosis of a primary immune deficiency disease
• Have been receiving licensed immunoglobulin infusions every 21-28 days for at least three months prior to this study

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.